Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Why there really is no need reason to continue the monthly letter imvho

Why there really is no need reason to continue the monthly letter imvho

posted on Feb 10, 2009 09:43AM

Alliacense will update on licenses, both here and abroad.

PTSC subsidiaries will update on developments/contracts.

Quarterly SEC filings will fill in the gaps, with the subsequent conference call fleshing out any areas that may need further clarification.



Having intially bought in because of the patents, I continue to hold/buy for the future developments. The patents are, in a sense, history. All that can be done to genrate income from them is being done in my very humble opinion. Once revalidated, there will be a flurry of new licensees, all of which will be announced in good time. As more license, there will be fewer to chase with a consequent fall-off in licensing revenues.

With the drop in licensing revenue, it will indeed play a decreasing role in total revenues, as per the pie chart, with the areas RG is developing playing an ever increasing part.

I am very excited at where PTSC is going, just as I was when I first saw the potential of the patents.

For those that need a monthly update, perhaps they could contact RG and request that some of the PTSC PRs contain a single paragraph overview of elements not contained in the main body.





Be well







Share
New Message
Please login to post a reply